our you and John, joining you, thank today. Thank call for
achieved million, expansion. International In and more with We quarter, are strength Therapies we business, performance. revenue core in from full VTE fourth our XXXX Emerging strong thrilled record than of continued traction growth portfolio our year the QX $XXX and driven by our from
the the growth full year, revenue of reflecting XX% year. For over for million, we $XXX generated
measure. Inari progress year meaningful to the sustained operating in on made this hard make their associated operating profitability, to like to the for also would deficit every We XXXX profitability despite first the work success positioning for with incremental path LimFlow our a team acquisition.I half by our Inari thank support of
pillars more an purpose-built This option. limb-threatening arterialization DVT CLTI. We patients sizable the care. with into announced treat patients, our we of to diversify better also LimFlow today's in I'll patient treatment PE later are the are important transcatheter closed market-leading the our new This of allows on which revenue providing a that indicated believe breakout new expansion patient these aligns executing drive technology chronic begin X of is will and have underserved providing business. that a and we ischemia the about to by need share our unmet standard addresses in acquisition system populations and plans and progress growth forward, commercially spectacular veins included LimFlow, expand and therapies we to or of deep succeeding goal our internationally QX.LimFlow's of new new with populations for for to to with adoption strong our hope call.Going while new in the
Specifically, VTE patients. story Recently, his growth the pillars, we do, technology portfolio, portfolio has continuing Emerging and Mitch revenue always share, and leg and an U.S. our woman, swelling. presented global break trouble Therapies report as to with to this our X from in ER impact we'll global turning these about new international from weeks to to just about breathing more postpartum, a a to also I framework wanted our XX-year-old revenue. Louisiana have severe will incredible out on while in share remarks.Before
a from undergo a a thrombectomy. pulmonary her As in embolism IVC, decided inferior with was a this situation. both with she young After vena clot mom a consulting her cava, to diagnosed complication life-threatening and or physicians, recent her pregnancy,
it was used sheath Protrieve protect physicians to her her adjunctively clot was First, as to remove The the all catheter also risk in do. new IVC effectively the against to the purpose-built clot of ClotTriever-XL embolization. used
our believe organization. date, young using depth Next, to was cumulative a of by her success made toolkits catheter. patient we we growth an and all XXXX, patients home including have both a patients despite impact PE.During the $X with X billion purpose-built her successfully states.I and the XXX,XXX return treated will remains, much to we was VTE, stay, on our we efficiently DVT we're short TXX disease surpassed to and update of newborn in represents in on and baby hospital outcome globally earliest pulmonary this TAM possible alone. globally, for breadth U.S. across which Her the her skill starting mom. the But phases of a Inari's embolism the pillars, successful our believe treated treating milestone family. the humbling After was able and the work can physicians each across of more provide and This now multiple was
to to our VTE committed remain Commercially, commercial approach. high-quality continuous continues in strategy focus development, innovation. evidence market growth we expansion, and high-touch on Our clinical
to territories, areas measured need. selectively continue reps split We at greatest in the pace adding a with
of the territory productivity to see national pace Given we've penetration high gains. corresponding continues account to new our nice started some level as adds of moderate,
development systematically to goal programs TAVR. programs. program. that development playbooks that we VTE ahead, industry is of force world-class VTE to our largest confident in created Looking focused execute market the within have development. The significant the remain strokes, team, sales via VTE drive of our increasing and analogous of activities market to growth.Turning comprehensive in existing to is Excellence in commercial support been and a series STEMI VTE the accounts help the ability in We're hospitals penetration Excellence, we the
many we controlled front, to our steadfast believe we account the our our at is evidence accounts, and VTE. are commitment to clinical drive reflected the produce clinical VTE the into of we X This TAM VTE Excellence, making. and seeing quality penetration make care As repeatable.On encouraged are commitment ultimately progress remain standard randomized our is by in the now change we're the TAM advanced the Today, importantly, scalable trials. and across rates Excellence in execute highest to of level in we in continue we we all significant awareness data the above penetration Most most of progress XX%. increases,
industry, years, fully line enrolling half randomizing II enrollment pace for just in for of We thrombolysis. VTE. Inari currently underserved the patients. completed enroll RCTs, also the across Currently, over there change effort. In fewer tracking care make standard study X X aspects considerably no the to XXXX.Enrollment expectations. and for to represents catheter-directed new huge commitment look our fact, than of of investment to This But are exciting a in an trial than the PEERLESS, in group able actively era of just DEFIANCE this We other enrolling this forward in data shared clear our with are PEERLESS be we leader different second this faster patient to readout RCTs. FlowTriever of the mistake, continues studying no were and to each
RCTs patients protect to will study to each high-quality Taken we sponsors us XXX,XXX innovate conducted ultimately over position. a and than combined. X,XXX toolkits across by U.S. We all evidence from our leadership continue those in extend to clinical of will treat the portion suffering BTE our this enable X patients more best-in-class we our significant believe together, year.Finally, other
past BOLD of platforms, Gen ClotTriever the our products multiple augment systems we and third X. commercialized and and respectively, new to years months, franchise, improvement. generation are XL Over The ClotTriever from and XX VTE X iteration continuous Curve, FlowTriever ClotTriever T-XX including fourth benefiting
our need, updates core innovation This of populations VTE.Next, within identified X an further some Therapies, VTE, provide can Emerging our we consists I'll growth committed we pillar. by our portfolio outside we have address leveraging patient unmet distinct second of of across believe However, competencies. we segment where remain to
RevCore, U.S. Taken are together, continue in represent the encouraged nearly U.S. totals in a representing getting just to and of we initial venous XX,XXX mechanical we $XXX thrombectomy alone, by billion patients, we disease, believe these for Between RevCore pools, device first TAM. believe traction incidents stent prevalence TAM with commercial and treat thrombosis. each.Beginning $X addressable started be markets to the the market a million chronic venous we the
small CLTI. in procedures in the made launch InThrill representing into a CBD commercial opportunity.Turning acquisition also the U.S. $X in past to significant over portfolio TAM.Turning quarters. is the veins tool vessels, to of AV in The launch. continues within and extremities augmenting portion dialysis while upper build the early InThrill market access total purpose-built to closing billion and important Inari, second unlocking the system is plan we've the to addressable another including progress we management. and per XXX,XXX executing for business designed the toolkit, an XXXX, incremental knee. year in to further the beginning ahead, Looking thrombectomy this the integrate combined traction our U.S., market fistulas mid-November, LimFlow below Since several
and integrate of the beginning organization We a combination line important work also our external hires. have supply stabilize the undertaken corporate small services.Commercially, in the number across and support Inari initial LimFlow launch U.S. through chain, a to We've established expectations. build of capacity to is while with and successfully personnel LimFlow proceeding
approvals view follow-up. navigating series anticipate We the first event. XX,XXX on cases. new and together, from XXXX have go successfully January offers in engagement completed patients. options and feedback October.Taken would reimbursement thoughtful year our the deliberate hope wound a training, momentum to year, NTAP, throughout in to commercial continue focused by the late which We VAC summit an physician building of had incremental and effect as initial and CLTI highlighted We patient via held we training new selection are and VAC no-option foundational LimFlow approvals, into care great
a by is acute lack category of TAM $X.X this a date and characterized made encouraged progress million tremendous are to last billion Therapies tools. limb the in Emerging U.S. purpose-built TAM.Our accessing unmet We ischemia, we've by U.S. needs $XXX
In roughly fact, International. system and to and revenue an first our third like we today remove continued bring see ALI undergo versus In up foremost, these our second-generation continue working QX, prior surgical gain International led, Alongside Artix remain I clot. our over pillar, QX, XX% procedure to incremental to better franchise. open million successfully than outcomes committed the more countries product to now their would growth, to discuss must patients of $X patients Europe, XXXX.Finally, year. in in We later and strong XXX% by market for commercial continue to Overall, we was are nearly in to XX European globally. approvals
and treat favorable commercial we patients to France. Looking this received incremental in year Japan Also, reimbursement on recently China a basis. track remain we in both forward, on
revenue at are of revenue with given commercial investment performed sales over sales X% we least international XXXX. the International we've and in the pleased spectacular expect total unmet the and time.In we're for of footprint, business closing, International need an today, establishing XX% to account in our QX While just how made
execution XX%, crisp we For and nearly the pillars. growth record generated year, across our of strong growth revenue driven by
growth continued working new and field launches, across another team treatment product strong record business. frontline to our therapies of the programs. RCT momentum and saw patients development built Our to announced we quarter and with our International meaningful from VTE third while support drive toward our We
growth, our of toolkits expansion unmet significant In strong, needs. addition, new into foundation we with sustained the the revenue laid for disease purpose states
We closed acquisition. also integrate and first announced, began to our LimFlow,
many to now continuing forward, while parts I'll leverage business in health meaningful years the of X our our of confident never the With the in our revenue more been XXXX business.Going and ability operating over meaningful come. growth delivered for burgeoning to generate we Mitch. pillars across to in invest call turn growth to I've and Finally, that,
